Biotechnology company.
AI-generated insights about Nektar Therapeutics from various financial sources
The speaker is long the stock but only in a 'very small amount,' indicating it's a speculative position with mild bullish conviction.
Mentioned as a neutral example of a company with a poor management track record that recently had a positive outcome, serving as a potential parallel for INMB's situation.
Viewed as a high-risk, high-reward speculation trading below its cash value. The speaker notes the asymmetric risk/reward (potential 10x return vs. 30% decline) makes it a tempting short-term trade ahead of data results, despite a history of failures.
The speaker is long the stock but only in a 'very small amount,' indicating it's a speculative position with mild bullish conviction.
Mentioned as a neutral example of a company with a poor management track record that recently had a positive outcome, serving as a potential parallel for INMB's situation.
Viewed as a high-risk, high-reward speculation trading below its cash value. The speaker notes the asymmetric risk/reward (potential 10x return vs. 30% decline) makes it a tempting short-term trade ahead of data results, despite a history of failures.